Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Stephenson

Showing results (521-530 of 570) with videos related to

Pageof 57
Sort By:
Human Molecular Genetics|July 23, 2003
Hereditary sensory neuropathy is caused by a mutation in the delta subunit of the cytosolic chaperonin-containing t-complex peptide-1 (Cct4 ) geneMing-Jen Lee, Dennis A Stephenson, Michael J Groves, et al.
Journal of Clinical and Translational Science|December 16, 2024
Source Data Verification (SDV) quality in clinical research: A scoping reviewMuayad Hamidi, Eric L Eisenstein, Maryam Y Garza, et al.
Heart Rhythm|August 3, 2021
Management and outcomes of atrial fibrillation in 241 healthy children and young adults: Revisiting "lone" atrial fibrillation-A multi-institutional PACES collaborative studyIqbal El Assaad, Benjamin H Hammond, Lukas D Kost, et al.
Cell Reports|July 11, 2025
Triglyceride metabolism controls inflammation and microglial phenotypes associated with APOE4Roxan A Stephenson, Jordy Sepulveda, Kory R Johnson, et al.
Journal of Medicinal Chemistry|May 17, 2013
Synthesis and pharmacological characterization of 4-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates: identification of new potent and selective metabotropic glutamate 2/3 receptor agonistsJames A Monn, Matthew J Valli, Steven M Massey, et al.
Heart Rhythm|October 26, 2011
Nonphysiologic noise early after defibrillator implantation in Canada: incidence and implications: a report from the Canadian Heart Rhythm Society Device CommitteeVidal Essebag, Jean Champagne, David H Birnie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumorsR L Drengler, J G Kuhn, L J Schaaf, et al.
Journal of Medicinal Chemistry|October 29, 2009
Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabineDavid M Bender, Jingqi Bao, Anne H Dantzig, et al.
Heart Rhythm|August 27, 2013
The Canadian experience with Durata and Riata ST Optim defibrillator leads: a report from the Canadian Heart Rhythm Society Device CommitteeMatthew T Bennett, Andrew C T Ha, Derek V Exner, et al.
Journal of Medicinal Chemistry|November 28, 2007
(S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: a potent, nonsteroidal, functional antagonist of the mineralocorticoid receptorMichael G Bell, Douglas L Gernert, Timothy A Grese, et al.
Pageof 57

Showing results (521-530 of 570) with videos related to

Sort By:
Pageof 57
Human Molecular Genetics|July 23, 2003
Hereditary sensory neuropathy is caused by a mutation in the delta subunit of the cytosolic chaperonin-containing t-complex peptide-1 (Cct4 ) geneMing-Jen Lee, Dennis A Stephenson, Michael J Groves, et al.
Journal of Clinical and Translational Science|December 16, 2024
Source Data Verification (SDV) quality in clinical research: A scoping reviewMuayad Hamidi, Eric L Eisenstein, Maryam Y Garza, et al.
Heart Rhythm|August 3, 2021
Management and outcomes of atrial fibrillation in 241 healthy children and young adults: Revisiting "lone" atrial fibrillation-A multi-institutional PACES collaborative studyIqbal El Assaad, Benjamin H Hammond, Lukas D Kost, et al.
Cell Reports|July 11, 2025
Triglyceride metabolism controls inflammation and microglial phenotypes associated with APOE4Roxan A Stephenson, Jordy Sepulveda, Kory R Johnson, et al.
Journal of Medicinal Chemistry|May 17, 2013
Synthesis and pharmacological characterization of 4-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates: identification of new potent and selective metabotropic glutamate 2/3 receptor agonistsJames A Monn, Matthew J Valli, Steven M Massey, et al.
Heart Rhythm|October 26, 2011
Nonphysiologic noise early after defibrillator implantation in Canada: incidence and implications: a report from the Canadian Heart Rhythm Society Device CommitteeVidal Essebag, Jean Champagne, David H Birnie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumorsR L Drengler, J G Kuhn, L J Schaaf, et al.
Journal of Medicinal Chemistry|October 29, 2009
Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabineDavid M Bender, Jingqi Bao, Anne H Dantzig, et al.
Heart Rhythm|August 27, 2013
The Canadian experience with Durata and Riata ST Optim defibrillator leads: a report from the Canadian Heart Rhythm Society Device CommitteeMatthew T Bennett, Andrew C T Ha, Derek V Exner, et al.
Journal of Medicinal Chemistry|November 28, 2007
(S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: a potent, nonsteroidal, functional antagonist of the mineralocorticoid receptorMichael G Bell, Douglas L Gernert, Timothy A Grese, et al.
Pageof 57